A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

@article{Gray2014API,
  title={A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.},
  author={Jhanelle E Gray and Eric B. Haura and Alberto Alejandro Chiappori and Tawee Tanvetyanon and Charles C. Williams and Mary C. Pinder-Schenck and Julie A. Kish and Jenny M. Kreahling and Richard M. Lush and Anthony M. Neuger and Leticia F Tetteh and Angela Akar and Xiuhua Zhao and Michael J. Schell and Gerold Bepler and Soner Altiok},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 6},
  pages={1644-55}
}
PURPOSE Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib. We evaluated this combination in patients with advanced NSCLC and head and neck cancer. EXPERIMENTAL DESIGN Eligible patients were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at four planned dose levels (DL). Pharmacokinetics… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS